Ascendis Pharma A/S
ASND
228.41
+2.36
+1.04%
Ascendis Pharma A/S
US · ASND
#1127 by market cap
Listed 2015
228.41
+2.36
+1.04%
Live - 5344 symbols - heartbeat 168s ago
· 2026-10-08 08:27
Pre-market
227.00
-0.62%
After-hours
228.41
0.00%
Overnight
229.84
+0.63%
- Market cap
- 15.03B
- P/E (TTM)i
- 18.23
- P/Bi
- 9.35
- EPSi
- -4.21
- Div yieldi
- 0.00%
- 52W posi
- 44%
Reader sentiment
Are you bullish or bearish on ASND?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Latest year +98.03% YoY
Margins
- Gross margin
- 86.82%
- Operating margin
- -18.92%
- Net margin
- -31.67%
Key ratios & quality
- Enterprise valuei
- 15.29B
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10.58M | 13.38M | 6.95M | 7.78M | 51.17M | 266.72M | 363.64M | 720.13M |
| Gross profit | -- | 13.38M | 6.95M | 4.26M | 39.04M | 222.32M | 319.38M | 625.22M |
| Selling & admin expenses | 25.06M | 48.47M | 76.67M | 160.18M | 215.85M | 264.41M | 284.08M | 448.04M |
| Research & development | 140.28M | 191.62M | 260.90M | 295.87M | 379.62M | 413.45M | 307.00M | 303.62M |
| Operating profit | -154.76M | -226.72M | -330.62M | -451.79M | -561.81M | -455.54M | -278.76M | -136.27M |
| Pretax profit | -130.49M | -218.25M | -419.17M | -383.94M | -577.82M | -474.14M | -373.24M | -212.65M |
| Tax | -394.00K | -234.00K | -219.00K | -367.00K | 5.38M | 7.30M | 4.84M | 15.38M |
| Net profit | -130.10M | -218.02M | -418.96M | -383.58M | -583.19M | -481.45M | -378.08M | -228.03M |
| Basic EPS | -3 | -5 | -8 | -7 | -10 | -9 | -7 | -4 |
| Diluted EPS | -3.17 | -4.69 | -8.28 | -7.00 | -10.40 | -8.55 | -6.53 | -3.76 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 100.95M | 158.05M | 213.63M | 247.50M | 246.60M | 339.29M |
| Gross profit | 83.44M | 126.60M | 191.28M | 223.90M | 229.09M | 311.63M |
| Selling & admin expenses | 101.05M | 105.71M | 111.69M | 135.00M | 145.23M | 171.68M |
| Research & development | 86.60M | 71.99M | 66.88M | 78.15M | 59.04M | 75.89M |
| Operating profit | -104.21M | -52.95M | 11.00M | 6.44M | 24.81M | 220.47M |
| Pretax profit | -93.57M | -35.01M | -57.37M | -26.71M | -48.18M | 230.09M |
| Tax | 1.06M | 3.85M | 3.62M | 6.86M | -677.52M | 23.12M |
| Net profit | -94.63M | -38.86M | -60.99M | -33.56M | 629.34M | 206.97M |
| Basic EPS | -2 | -1 | -1 | -1 | 10 | 3 |
| Diluted EPS | -1.58 | -0.82 | -1.00 | -0.55 | 9.75 | 2.83 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 292.91M | 611.17M | 740.13M | 805.89M | 923.47M | 702.72M | 1.06B | 1.11B |
| Cash & ST investments | 277.86M | 598.11M | 718.80M | 682.06M | 735.46M | 399.44M | 559.54M | 616.04M |
| Inventory | -- | -- | 0 | 75.41M | 130.67M | 208.93M | 295.61M | 301.53M |
| Total assets | 318.97M | 676.73M | 979.79M | 1.08B | 1.09B | 825.59M | 1.18B | 1.30B |
| Total current liabilities | 38.92M | 47.99M | 52.80M | 100.36M | 716.78M | 736.51M | 907.86M | 1.07B |
| Short-term debt | -- | 5.90M | 6.86M | 7.00M | 412.98M | 421.27M | 491.54M | 486.53M |
| Long-term debt | -- | -- | -- | 97.97M | 95.40M | 223.00M | 365.08M | 385.25M |
| Total liabilities | 38,918,000.00 | 79,618,000.00 | 141,082,000.00 | 201,286,000.00 | 826,390,000.00 | 971,284,000.00 | 1,285,201,000.00 | 1,465,391,000.00 |
| Total equity | 280.05M | 597.11M | 838.71M | 883.64M | 263.35M | -145.70M | -105.71M | -162.82M |
| Retained earnings | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 921.49M | 952.96M | 1.02B | 1.11B | 1.12B | 1.39B |
| Cash & ST investments | 517.92M | 494.05M | 539.09M | 616.04M | 572.82M | 812.26M |
| Inventory | 293.07M | 303.38M | 302.02M | 301.53M | 314.34M | 310.58M |
| Total assets | 1.06B | 1.09B | 1.15B | 1.30B | 2.00B | 2.29B |
| Total current liabilities | 885.51M | 935.00M | 986.48M | 1.07B | 1.13B | 464.89M |
| Short-term debt | 489.96M | 462.35M | 482.28M | 486.53M | 510.56M | 65.43M |
| Long-term debt | 357.31M | 330.19M | 331.37M | 385.25M | 386.11M | 384.64M |
| Total liabilities | 1,251,245,000.00 | 1,275,474,000.00 | 1,328,825,000.00 | 1,465,391,000.00 | 1,515,306,000.00 | 849,529,000.00 |
| Total equity | -189.81M | -187.57M | -174.08M | -162.82M | 487.97M | 1.44B |
| Retained earnings | -2.66B | -2.67B | -- | -- | -- | -1.88B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -138.80M | -175.94M | -271.55M | -417.65M | -495.70M | -467.36M | -306.20M | 53.90M |
| Depreciation & amortization | 880.00K | 6.69M | 9.45M | 15.39M | 17.96M | 18.91M | 17.71M | 17.70M |
| Free cash flow | -141.45M | -181.10M | -293.10M | -441.88M | -510.19M | -469.80M | -307.62M | 45.41M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 216.39M | 480.25M | 580.54M | 346.28M | -105.31M | 0 | 309.91M | -17.40M |
| Ending cash balance | 277.86M | 598.11M | 584.52M | 446.27M | 444.77M | 392.16M | 559.54M | 616.04M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -14.31M | -7.34M | 2.15M | 73.40M | -7.72M | 281.68M |
| Depreciation & amortization | 4.55M | 4.31M | 4.02M | 4.82M | 4.22M | 4.57M |
| Free cash flow | -14.31M | -12.38M | 2.10M | 70.01M | -7.72M | 270.73M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -17.40M | 0 | 0 | 0 | -51.86M | -51.56M |
| Ending cash balance | 517.92M | 494.05M | 539.09M | 616.04M | 572.82M | 812.26M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -55.68 | -49.71 | -58.36 | -44.54 | -101.69 | -818.43 | -- | -- |
| ROA %i | -49.10 | -43.79 | -50.58 | -37.16 | -53.64 | -50.27 | -37.71 | -18.37 |
| ROIC %i | -57.35 | -47.74 | -53.55 | -39.64 | -62.99 | -71.58 | -- | -- |
| 5-year avg ROE %i | -49.33 | -51.85 | -55.60 | -55.28 | -62.00 | -214.55 | -- | -- |
| EBIT margin %i | -1,232.06 | -1,622.65 | -6,001.09 | -4,886.00 | -1,038.91 | -161.25 | -84.63 | -18.33 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | 6.31 |
| Current ratioi | 7.53 | 12.74 | 14.02 | 8.03 | 1.29 | 0.95 | 1.17 | 1.04 |
| Quick ratioi | 7.21 | 12.58 | 13.75 | 7.03 | 1.06 | 0.62 | 0.81 | 0.72 |
| Debt / assetsi | 0.00 | 5.41 | 9.39 | 9.67 | 46.65 | 78.04 | 72.63 | 66.93 |
| LT debt / equityi | -- | 5.14 | 10.15 | 11.09 | 36.23 | -- | -- | -- |
| Interest coveragei | -1,026.49 | -177.75 | -217.55 | -97.17 | -11.52 | -9.76 | -4.70 | -1.64 |
| Revenue CAGR (3Y) %i | 9.23 | 42.67 | 65.64 | -9.75 | 56.41 | 237.26 | 260.25 | 141.43 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | 332.65 | 118.78 |
| ROA %i | -36.66 | -29.37 | -20.72 | -18.37 | 32.36 | 43.97 |
| ROIC %i | -- | -- | -- | -- | 55.16 | 62.34 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -82.76 | -36.55 | -22.14 | -18.33 | -7.41 | 16.53 |
| FCF / sales %i | -- | -- | -- | 6.31 | 6.01 | 32.01 |
| Current ratioi | 1.04 | 1.02 | 1.03 | 1.04 | 1.00 | 2.99 |
| Quick ratioi | 0.67 | 0.66 | 0.70 | 0.72 | 0.68 | 2.23 |
| Debt / assetsi | 79.82 | 72.85 | 70.46 | 66.93 | 44.76 | 19.69 |
| LT debt / equityi | -- | -- | -- | -- | 79.12 | 26.78 |
| Interest coveragei | -9.21 | -2.12 | -1.79 | -1.64 | -0.62 | 2.30 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- YORVIPATH® is the largest reported line at 74.31% of revenue, across 6 reported segments.
- The next-largest line, SKYTROFA®, is a distant second at 16.27% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
YORVIPATH®74.31%
SKYTROFA®16.27%
Milestones5.02%
YUVIWEL®2.23%
Services and clinical supply1.43%
Licenses0.73%
Quote time 2026-10-08 08:27:11 · For reference only, not investment advice and not tailored to your situation.